Gregory Smith on strategic rationale
From Medtronic PLC ($MDT) Q4 2025 Earnings Call · · Castify Earnings Call
“Diabetes is predominantly B2C whereas Medtronic our businesses are predominantly B2B. We sell different types of products to different types of customers. Medtronic's commercial manufacturing and technology platform synergies are less applicable to the diabetes business given their distinct customer go-to-market and supply chain infrastructure.”
On , Gregory Smith, Executive Vice President of Enterprise Operations at Medtronic, spoke about strategic rationale during Medtronic PLC ($MDT) Q4 2025 Earnings Call on Castify Earnings Call.
About Gregory Smith
During Medtronic's fiscal fourth quarter 2025 earnings call on May 1, 2025, an executive noted that the supply chain team under Gregory Smith, Executive Vice President of Enterprise Operations, "has kicked off a lot of very positive initiatives" and that the company is "starting to see the results" with expectations of further progress. The comment came as part of a broader discussion about margin improvement opportunities.